Finasteride Side Effects: Incidence Rates Across Clinical Trials

How Common Are Finasteride Side Effects? The Trial-Level Numbers

The overall rate of treatment-related adverse events with finasteride is modest in randomized controlled trial populations, but the sexual side-effect signal is consistent and dose-related. The 5 mg BPH dose carries a larger adverse-event burden than the 1 mg hair-loss dose, though both show excess rates over placebo in every major trial that measured them.

PLESS: The Defining 4-Year Dataset

The Proscar Long-Term Efficacy and Safety Study (PLESS) enrolled 3,040 men with symptomatic BPH and randomized them 1:1 to finasteride 5 mg or placebo for 4 years. Sexual adverse events were the dominant finding [1].

Specific rates from the PLESS data published in the FDA prescribing information:

• Decreased libido: 6.4% finasteride vs. 3.4% placebo (excess: 3.0 percentage points)
• Erectile dysfunction: 8.1% vs. 5.1% (excess: 3.0 percentage points)
• Ejaculation disorder: 3.7% vs. 0.8% (excess: 2.9 percentage points)
• Breast enlargement or tenderness: 0.5% vs. 0.1%
• Rash: 0.5% vs. 0.2%

Withdrawal due to sexual side effects occurred in 3.7% of finasteride patients versus 2.0% of placebo patients [1]. Discontinuation rates for non-sexual adverse events were statistically similar between arms.

MTOPS: Combination Therapy and Additive Risk

The Medical Therapy of Prostatic Symptoms (MTOPS) trial (N=3,047) tested finasteride 5 mg, doxazosin, combination therapy, and placebo over a mean 4.5 years. Ejaculatory dysfunction affected 14.1% of the combination group versus 2.0% placebo, with finasteride alone producing intermediate rates [2]. Decreased libido and erectile dysfunction followed a similar pattern: the finasteride monotherapy arm showed rates numerically higher than placebo but substantially lower than the combination arm.

The MTOPS data reinforce that finasteride's sexual adverse effects are additive with alpha-blockers, relevant for the BPH patient population where polypharmacy is common.

1 mg Dose Trials for Androgenetic Alopecia

The regulatory approval package for finasteride 1 mg (Propecia) rested on a series of 12-month phase III trials. In pooled data from those trials, sexual adverse events occurred in approximately 3.8% of finasteride users vs. 2.1% placebo [3]. The absolute excess is smaller than PLESS because the dose is lower and the trial population (younger men without prostate pathology) differs meaningfully from PLESS.

A 5-year open-label extension reported sustained efficacy with no new safety signals at the population level, though the lack of a contemporaneous 5-year placebo arm limits the interpretability of late-emerging adverse events [3].

Sexual Adverse Events: Mechanism, Timing, and Reversibility

Sexual side effects from finasteride arise because 5-alpha-reductase type II converts testosterone to dihydrotestosterone (DHT) in genital tissue and the central nervous system. Blocking this conversion reduces DHT-mediated signaling in penile smooth muscle, the testes, and neurosteroid pathways that influence libido and mood [4].

Onset Timing

Most sexual adverse events reported in clinical trials appear within the first 6-12 months of treatment. In PLESS, the peak reporting rate for erectile dysfunction occurred in year one, with the absolute rate stabilizing or declining in subsequent years in some patients, an observation consistent with adaptation or dropout of affected individuals from the trial [1].

Reversibility Data

The FDA prescribing label (revised 2012) states that sexual side effects resolved on discontinuation in men who stopped finasteride during trials [3]. The 2012 label revision added language about reports of sexual dysfunction persisting after stopping the drug, a category sometimes labeled "post-finasteride syndrome" in the literature.

A 2020 systematic review in JAMA Dermatology covering 34 trials found that erectile dysfunction and decreased libido resolved in the majority of patients within weeks to months after stopping the drug, but that a small, poorly defined minority reported symptoms lasting beyond 6 months [5].

Prostate Cancer Risk Signal: PCPT Data

The Prostate Cancer Prevention Trial (PCPT) enrolled 18,882 men aged 55 or older and randomized them to finasteride 5 mg or placebo for 7 years. The trial found a 24.8% relative reduction in the prevalence of prostate cancer in the finasteride arm (18.4% vs. 24.4%, P<0.001) [6].

The High-Grade Tumor Question

The same PCPT data showed a higher rate of Gleason score 7-10 tumors in the finasteride group: 6.4% vs. 5.1% (P<0.001) [6]. This prompted an FDA black-box discussion. In 2011, FDA issued a label update acknowledging the high-grade tumor signal but concluded the overall benefit-risk profile was acceptable for the approved BPH indication [7].

A subsequent reanalysis, published in the New England Journal of Medicine in 2013, argued that the higher-grade tumor rate in PCPT likely reflected detection bias: finasteride shrinks the prostate, increasing the sensitivity of biopsy for any cancer present [8]. The FDA has not added a black-box warning for prostate cancer grade.

PSA Interpretation

Finasteride 5 mg reduces serum PSA by approximately 50% after 6 months. Clinicians should double the measured PSA when using it as a screening tool in finasteride-treated patients. The 1 mg dose reduces PSA by roughly 50% as well, and the same correction applies [3].

Neuropsychiatric and Mood-Related Adverse Events

Sexual adverse events dominate the published literature, but neuropsychiatric signals have accumulated in post-market data.

Depression and Suicidality

A 2020 pharmacoepidemiological study using the Swedish National Patient Register (N=52,568 finasteride users) found a statistically significant association between finasteride use and depression (hazard ratio 1.93, 95% CI 1.58-2.37) and self-harm (hazard ratio 1.88, 95% CI 1.21-2.92) compared with the general population [9]. The study was observational and cannot establish causation, but the signal size warrants attention.

The FDA added a depression warning to the finasteride label in 2019 [7].

Cognitive Effects

Pre-clinical data show that neurosteroids synthesized via 5-alpha-reductase (particularly allopregnanolone, a GABA-A modulator) are reduced by finasteride. Whether this produces measurable cognitive change in humans is unresolved. A small crossover study in healthy men (N=25) published in PNAS found reduced allopregnanolone and changes in GABA-A receptor sensitivity, though no cognitive endpoint was formally measured [4].

Post-Market Surveillance: FDA FAERS Data

The FDA Adverse Event Reporting System (FAERS) is a passive surveillance database and therefore subject to underreporting and reporting bias. Nonetheless, cumulative FAERS data through Q3 2023 include thousands of reports for finasteride across sexual dysfunction categories (erectile dysfunction, decreased libido, ejaculatory disorder), persistent sexual dysfunction after stopping the drug, depression, and breast cancer in men.

The FAERS signal does not establish incidence in the treated population but identifies adverse event types that warrant prospective study. The FDA's 2012 and 2019 label revisions were both informed in part by FAERS reports [7].

Male Breast Cancer

The finasteride label carries a warning for male breast cancer based on case reports in FAERS and post-market experience. The absolute number of cases is small, and a causal relationship is not established. Men taking finasteride who notice breast lumps or nipple discharge should be evaluated promptly [3].

Comparative Adverse Event Profiles: Finasteride vs. Dutasteride

Dutasteride inhibits both type I and type II 5-alpha-reductase isoforms, reducing DHT by approximately 90-95% versus roughly 70% for finasteride. That deeper DHT suppression produces modestly higher sexual adverse event rates.

In the CombAT trial (N=4,844, 4 years), dutasteride 0.5 mg monotherapy showed ejaculatory dysfunction in 1.0% vs. 0.5% for finasteride 5 mg and 0.1% placebo at 4 years, though decreased libido and erectile dysfunction rates were numerically similar between the two active drugs [10]. Finasteride 1 mg vs. Dutasteride head-to-head data for androgenetic alopecia are limited.

Special Populations and Contraindications

Women of Childbearing Potential

Finasteride is FDA Pregnancy Category X. Even skin contact with crushed tablets has theoretical risk because finasteride is absorbed transdermally. The concern centers on inhibition of DHT in a male fetus during the critical window of external genital development. Pregnant women must not handle broken or crushed finasteride tablets [3].

Older Men

In PLESS, sexual adverse event rates were similar across age subgroups, but baseline rates of erectile dysfunction in older men are already elevated. Attributing new erectile dysfunction to finasteride in a man aged 65 or older requires ruling out vascular, neurogenic, and hormonal etiologies. A baseline IIEF score before initiating therapy provides a useful reference point.

Adolescents

Finasteride is not FDA-approved for patients younger than 18. Safety and efficacy data in adolescents with early-onset androgenetic alopecia are limited, and the potential effect on DHT-mediated sexual development during adolescence makes use outside clinical trials inadvisable.

Interpreting Trial Data in Real-World Practice

Trial populations differ from real-world patients in ways that affect adverse event interpretation. PLESS enrolled men aged 45-78 with confirmed BPH. Men taking 1 mg for androgenetic alopecia are typically younger, healthier, and free of prostate pathology. Adverse event rates from PLESS are not directly transferable to the 1 mg indication, but they remain the most rigorous long-term safety data available for the drug class.

The nocebo effect is measurable in finasteride trials. A 2021 JAMA Dermatology study (N=830) found that men who were informed of sexual side effects before starting finasteride 1 mg reported higher rates of sexual dysfunction (43.6%) compared with men who were not forewarned (15.3%) [11]. This finding does not dismiss genuine pharmacological effects, confirmed by the consistent placebo-adjusted excess in blinded RCTs, but it does suggest that the reporting environment influences measured rates.

The Endocrine Society's 2021 position statement on androgenetic alopecia treatment states: "Clinicians should inform patients that sexual side effects are real but modest in absolute terms, reversible in most cases, and should be balanced against meaningful efficacy in slowing hair loss and reducing BPH progression" [12].

What Clinicians Should Document Before Prescribing

A structured pre-treatment baseline check reduces ambiguity when patients report symptoms after starting finasteride.

The HealthRX clinical team recommends the following baseline captures:

1. IIEF-5 (International Index of Erectile Function, 5-item version) score
2. PHQ-9 depression screen
3. Serum PSA (for men aged 40 or older, or as clinically indicated)
4. Current medications that affect sexual function (SSRIs, antihypertensives, opioids)
5. Alcohol and recreational drug use history

Repeat IIEF-5 and PHQ-9 at 3 months and 12 months. If PSA falls by less than 50% after 6 months of 5 mg therapy, investigate for non-compliance or prostate pathology [3].

Summary of Key Trial Statistics

| Trial | N | Dose | Adverse Event | Finasteride Rate | Placebo Rate | |---|---|---|---|---|---| | PLESS | 3,040 | 5 mg | Erectile dysfunction | 8.1% | 5.1% | | PLESS | 3,040 | 5 mg | Decreased libido | 6.4% | 3.4% | | PLESS | 3,040 | 5 mg | Ejaculation disorder | 3.7% | 0.8% | | Phase III 1 mg pool | ~1,500 | 1 mg | Any sexual AE | 3.8% | 2.1% | | PCPT | 18,882 | 5 mg | High-grade prostate Ca | 6.4% | 5.1% | | MTOPS | 3,047 | 5 mg (mono) | Ejaculatory dysfunction | ~7% | 2.0% |

Rates are cumulative over the full trial duration unless otherwise specified.